Blocking immune checkpoint regulators such CTLA-4 and PD-1/PD-L1 pathway in solid tumors [137], as well as customized T cell therapy in acute lymphoblastic leukemia (ALL), cancer immunotherapy, as a monotherapy or in combination with other treatments, has recently ushered in a new age. This evidence concerns the gene PDCD1 and cancer.